Literature DB >> 2372984

Detection of tumour necrosis factor/cachectin in pleural effusion of patients with lung cancer.

Y Ishii1, Y Uchiyama, S Hasegawa, T Kinoshita, K Mitsui, H Kojima, T Fujita.   

Abstract

We have found that the pleural effusion obtained from a patient with lung cancer (adenocarcinoma) has cytotoxic activity against the patient's lung cancer cells. This finding occurred in the course of establishing a lung cancer cell line from the patient's pleural effusion. The cytotoxic factor was partially purified from the pleural effusion and characterized. It had cytotoxicity against L-929 mouse fibroblasts in the standard 18-h killing assay of tumour necrosis factor (TNF). By molecular sieving chromatography, the activity appeared at molecular weight of 50,000. This activity was completely blocked by a monoclonal antibody to TNF. From these results, we conclude that the cytotoxic factor in the pleural effusion is TNF. The concentration of TNF in the pleural effusion was 34.5 pg/ml by radioimmunoassay. In addition, we detected TNF activity and protein in two other cases of carcinomatous pleural effusion. Therefore, it would appear that in vivo TNF displays cytotoxic activity against cancer cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2372984      PMCID: PMC1535206          DOI: 10.1111/j.1365-2249.1990.tb03291.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  11 in total

Review 1.  Cachectin: more than a tumor necrosis factor.

Authors:  B Beutler; A Cerami
Journal:  N Engl J Med       Date:  1987-02-12       Impact factor: 91.245

2.  An endotoxin-induced serum factor that causes necrosis of tumors.

Authors:  E A Carswell; L J Old; R L Kassel; S Green; N Fiore; B Williamson
Journal:  Proc Natl Acad Sci U S A       Date:  1975-09       Impact factor: 11.205

3.  Rapid colorimetric assay for cell viability: application to the quantitation of cytotoxic and growth inhibitory lymphokines.

Authors:  L M Green; J L Reade; C F Ware
Journal:  J Immunol Methods       Date:  1984-05-25       Impact factor: 2.303

4.  Increased production of tumor necrosis factor and prostaglandin E2 by monocytes in cancer patients and its unique modulation by their plasma.

Authors:  K Nara; H Odagiri; M Fujii; Y Yamanaka; M Yokoyama; T Morita; M Sasaki; M Kon; T Abo
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

5.  Tumor necrosis factor (TNF).

Authors:  L J Old
Journal:  Science       Date:  1985-11-08       Impact factor: 47.728

6.  Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease.

Authors:  A Waage; A Halstensen; T Espevik
Journal:  Lancet       Date:  1987-02-14       Impact factor: 79.321

7.  Tumour necrosis factor is a compact trimer.

Authors:  P Wingfield; R H Pain; S Craig
Journal:  FEBS Lett       Date:  1987-01-26       Impact factor: 4.124

8.  Human tumor necrosis factor. Production, purification, and characterization.

Authors:  B B Aggarwal; W J Kohr; P E Hass; B Moffat; S A Spencer; W J Henzel; T S Bringman; G E Nedwin; D V Goeddel; R N Harkins
Journal:  J Biol Chem       Date:  1985-02-25       Impact factor: 5.157

9.  Evidence for tumour necrosis factor/cachectin production in cancer.

Authors:  F Balkwill; R Osborne; F Burke; S Naylor; D Talbot; H Durbin; J Tavernier; W Fiers
Journal:  Lancet       Date:  1987-11-28       Impact factor: 79.321

10.  Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells.

Authors:  B Beutler; J Mahoney; N Le Trang; P Pekala; A Cerami
Journal:  J Exp Med       Date:  1985-05-01       Impact factor: 14.307

View more
  1 in total

1.  Production of interleukin-1 beta and tumour necrosis factor-alpha in patients with benign or malignant ovarian tumours.

Authors:  J Punnonen; P K Heinonen; T Kuoppala; C T Jansen; R Punnonen
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.